Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02441803
Recruitment Status : Active, not recruiting
First Posted : May 12, 2015
Last Update Posted : May 23, 2019
Sponsor:
Information provided by (Responsible Party):
M.D. Anderson Cancer Center

Tracking Information
First Submitted Date  ICMJE May 5, 2015
First Posted Date  ICMJE May 12, 2015
Last Update Posted Date May 23, 2019
Actual Study Start Date  ICMJE September 14, 2015
Estimated Primary Completion Date September 2022   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: May 7, 2015)
  • Overall Response (OR) [ Time Frame: 4 months ]
    Participants classified as achieving overall response if they have complete response (CR) or CR without platelet recovery (CRp) or CR with insufficient hematological recovery (CRi) 4 months after initial treatment. Overall response (CR + CRp + CRi) rates and their posterior 95% credible intervals estimated using a beta distribution with a prior of Beta (0.4, 1.6).
  • Treatment-Related Mortality (TRM) [ Time Frame: 4 months ]
    Participants classified as having treatment-related death if they die due to a symptom that is possibly, probably, or definitely related to therapy within 4 months of starting treatment. TRM rate at 4 months post treatment initiation reported using a prior of Beta (1.2, 0.8).
Original Primary Outcome Measures  ICMJE Same as current
Change History Complete list of historical versions of study NCT02441803 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: May 7, 2015)
Overall Survival (OS) [ Time Frame: 2 years ]
OS defined as the time from starting treatment until death from any cause. Patients who are alive at the time of analysis will be censored on the date of last contact.
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)
Official Title  ICMJE Allogeneic Hematopoietic Stem Cell Transplantation as Initial Salvage Therapy for Patients With Primary Induction Failure Acute Myeloid Leukemia Refractory to High-Dose Cytarabine-Based Induction Chemotherapy
Brief Summary

Objectives:

Primary Objectives:

  1. To determine the safety and feasibility of allogeneic hematopoietic stem cell transplantation (AHSCT) as initial salvage treatment for patients with primary induction failure (PIF) acute myeloid leukemia (AML).
  2. To determine efficacy of AHSCT following decitabine, clofarabine, idarubicin, and cytarabine (DCIA) salvage chemotherapy evaluated by overall response rate (RR), defined as complete response (CR) or CR without platelet recovery (CRp) or CR with insufficient hematological recovery (CRi).

Secondary Objectives:

  1. To determine the percentage of patients with PIF AML eligible for AHSCT after up to 2 courses of induction chemotherapy.
  2. To determine the early treatment-related mortality (TRM) (within first 4 weeks of first salvage chemotherapy regimen with DCIA and day 100 TRM after AHSCT.
  3. To determine the efficacy DCIA regimen as salvage chemotherapy for patients with PIF AML (% of patients who achieve </=5% bone marrow blasts prior to AHSCT.
  4. To determine the TRM at 1 year, relapse rate (RR), overall survival (OS) and event-free survival (EFS) for patients with PIF AML treated with DCIA followed by early AHSCT.
Detailed Description

Salvage Chemotherapy Before Transplant:

Study Drug Administration:

On Days 1-5, you will receive decitabine 1 time each day by vein over about 1-3 hours.

On Days 6-10:

  • You will receive cytarabine 1 time a day by vein over about 1-3 hours.
  • On Days 6-8 only, you will receive idarubicin 1 time a day by vein over about 30 minutes.
  • On Days 6-9 only, you will receive clofarabine 1 time a day by vein over about 1-2 hours.

Study Visits:

After your last study drug dose:

  • Blood (about 2 teaspoons) will be drawn to check your kidney and liver function.
  • You will have an echocardiogram (ECHO) or multigated acquisition (MUGA) scan to check your heart function.
  • You will have a lung function test.

On Day 21 (+/- 7 days), you will have a bone marrow biopsy/aspirate to check the status of the disease. To collect a bone marrow biopsy/aspirate, an area of the hip is numbed with anesthetic, and a small amount of bone and bone marrow is withdrawn through a large needle.

If the results of your bone marrow biopsy/aspirate, blood tests, and heart and lung function tests show that you are eligible to receive an allogeneic stem cell transplant, you will be asked to sign a separate informed consent for the transplant.

If the results of your bone marrow aspirate/biopsy, blood tests, and heart and lung function tests show that you are not eligible to receive an allogeneic stem cell transplant you will not receive it. The study staff will call you and ask how you are feeling and about any other drugs you may be taking every 3 months for 2 years after your last study drug dose. These calls should last about 5 minutes each.

If you are found to NOT be eligible to receive an allogeneic stem cell transplant, your doctor will discuss other treatment options with you.

Stem Cell Transplant:

Study Drug Administration, Pharmacokinetic (PK) Testing, and Stem Cell Transplant:

For a stem cell transplant, the days before you receive your stem cells are called minus days. The day you receive the stem cells is called Day 0. The days after you receive the stem cells are called plus days.

You will receive a dose of busulfan by vein over about 45 minutes to 1 hour as an outpatient or as an inpatient on Day -8. With the first busulfan infusion, blood (about 1 teaspoon each time) will be drawn for pharmacokinetic (PK) testing about 11 times over 11 hours before and after you receive your first dose of busulfan. PK testing measures the amount of study drug in the body at different time points. The study staff will tell you the blood testing schedule. Test doses are used to study how your body breaks down busulfan and decide the dose of busulfan that you will receive on Days -6 through -3.

A heparin lock line will be placed in your vein before the PK testing to lower the number of needle sticks needed for these draws. If for any reason it is not possible for the PK tests to be performed, you will receive the standard dose of busulfan.

On Day -7, you will rest.

On Days -6 through -3, you will receive fludarabine by vein over 1 hour, clofarabine by vein over 1 hour, and then busulfan by vein over 3 hours.

On Days -3 and -2, if you will receive stem cells from a matched unrelated donor, you will receive ATG by vein over 4 hours each day.

On Day -2, if you will receive stem cells from a haploidentical donor, you will receive total body irradiation (TBI) one time. TBI involves the delivery of high doses of radiation designed to destroy cancer cells and/or lower the immune system in order to lower the risk of the body rejecting the new stem cells.

On Day -2, you will receive tacrolimus by vein over 24 hours every day until you are able to take it by mouth. Tacrolimus is designed to weaken the immune system and lower the risk of graft-versus-host-disease (GVHD - a reaction of the donor's immune cells against your body). After you are able to take tacrolimus by mouth, you will take it every day for about 6 months, or until the doctor thinks it is safe to stop.

On Day -1, you will rest. If you will receive stem cells from a matched sibling donor, you will rest on Days -2 and -1.

On Day 0, you will receive the donor's stem cells by vein. The infusion will last anywhere from about 30 minutes to several hours.

If you will receive stem cells from a haploidentical donor:

After the stem cell infusion, you will receive tacrolimus to help lower the risk of GVHD. Tacrolimus will be given by vein non-stop for about 2 weeks. After the 2 weeks of taking tacrolimus by vein, you will take tacrolimus by mouth as a pill for at least 4 months after the transplant.

On Days +3 and +4, you will receive cyclophosphamide by vein over 3 hours. Cyclophosphamide is given to lower the immune system in order to lower the risk of GVHD.

If you receive stem cells from a matched sibling or matched unrelated donor:

On Days +1, +3, +6, and +11, you will receive methotrexate by vein over 30 minutes. Methotrexate is given to help prevent GVHD.

Study Testing:

Before you are sent home from the hospital and/or clinic, you will receive additional written instructions. These instructions will include how often you will come to the hospital/clinic, which standard drugs you will take at home, and what side effects you may have and what to do for them.

After finishing the chemotherapy and transplant, your follow-up care will be routine standard of care follow-up that all patients receiving allogeneic stem cell transplantation receive. At each visit, you will have a physical exam. You will be asked about any side effects you may have had. Blood (about 1 tablespoon) will be drawn for routine tests. If the doctor thinks it is needed, you will have a bone marrow aspiration to check the status of the disease. To collect a bone marrow aspirate, an area of the hip or other site is numbed with anesthetic, and a small amount of bone marrow is withdrawn through a large needle.

Length of Treatment:

After 2 years, your participation in this study will be over. You may be taken off study early if the disease gets worse, if your transplant does not "take" (graft failure), if you are unable to follow study directions, if your doctor thinks it is in your best interest, if the study is stopped, or if you choose to leave the study early.

If for any reason you want to leave the study early, you must talk to the study doctor. It may be life-threatening to leave the study after you have started to receive the study drugs but before you receive the stem cell transplant because your blood cell counts will be dangerously low.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Leukemia
Intervention  ICMJE
  • Drug: Busulfan
    Test dose Busulfan 32 mg/m2 given by vein on Day -8. Busulfan AUC 5,000 by vein on Days -6 to -3.
    Other Names:
    • Busulfex
    • Myleran
  • Drug: Fludarabine
    Fludarabine 10 mg/m2 by vein on Days -6 to -3.
    Other Names:
    • Fludarabine Phosphate
    • Fludara
  • Drug: Clofarabine

    Salvage Chemotherapy Before Transplant: Clofarabine 15 mg/m2 by vein on Days 6 - 9.

    Stem Cell Transplant: Clofarabine 40 mg/m2 by vein on Days -6 to -3.

    Other Names:
    • Clofarex
    • Clolar
  • Radiation: Total Body Irradiation (TBI)
    Total body irradiation (TBI) delivered at 2Gy on Day -2.
    Other Names:
    • TBI
    • XRT
  • Drug: Thymoglobulin
    Thymoglobulin 2.0 mg/Kg by vein on Days -3 and -2.
    Other Names:
    • ATG (Rabbit)
    • Rabbit Antithymocyte Globulin
    • Rabbit Antilymphocyte Globulin
    • Rabbit ATG
    • rATG
  • Biological: Stem Cell Infusion
    Fresh or cryopreserved bone marrow or peripheral blood (PB) progenitor cells infused on Day 0. Goal is to infuse 4 X 106 CD34+ cells/kg if PB or >3.0 X 108 marrow mononuclear cells/kg if bone marrow.
  • Drug: Cyclophosphamide
    Cyclophosphamide 50 mg/kg by vein on Days +3 and +4.
    Other Names:
    • Cytoxan
    • Neosar
  • Drug: Tacrolimus
    Tacrolimus 0.015 mg/kg/day by vein or mouth on Day +5.
    Other Name: Prograf
  • Drug: Mycophenolate mofetil
    Mycophenolate mofetil 15 mg/kg/dose by vein or by mouth three times a day from Day +5 to Day+100.
    Other Names:
    • MMF
    • CellCept
  • Drug: Decitabine
    20 mg/m2 by vein on Days 1 - 5.
    Other Name: Dacogen
  • Drug: Cytarabine
    1 g/m2 by vein on Days 6 - 10.
    Other Names:
    • Ara-C
    • Cytosar
    • DepoCyt
    • Cytosine Arabinosine Hydrochloride
  • Drug: Idarubicin
    10 mg/m2 by vein on Days 6 - 8.
    Other Name: Idamycin
Study Arms  ICMJE
  • Experimental: Matched Sibling Donor Group

    Salvage Chemotherapy Before Transplant: Decitabine 20 mg/m2 by vein on Days 1 - 5. Cytarabine 1 g/m2 by vein on Days 6 - 10. Idarubicin 10 mg/m2 by vein on Days 6 - 8. Clofarabine 15 mg/m2 by vein on Days 6 - 9.

    Stem Cell Transplant: Test dose Busulfan 32 mg/m2 by vein on Day -8. Busulfan AUC 5,000 by vein on Days -6 to -3. Fludarabine 10 mg/m2 by vein on Days -6 to -3. Clofarabine 40 mg/m2 by vein on Days -6 to -3. Stem cell infusion performed on Day 0.

    Interventions:
    • Drug: Busulfan
    • Drug: Fludarabine
    • Drug: Clofarabine
    • Biological: Stem Cell Infusion
    • Drug: Decitabine
    • Drug: Cytarabine
    • Drug: Idarubicin
  • Experimental: Haploidentical Donor Group

    Salvage Chemotherapy Before Transplant: Decitabine 20 mg/m2 by vein on Days 1 - 5. Cytarabine 1 g/m2 by vein on Days 6 - 10. Idarubicin 10 mg/m2 by vein on Days 6 - 8. Clofarabine 15 mg/m2 by vein on Days 6 - 9.

    Stem Cell Transplant: Test dose Busulfan 32 mg/m2 given by vein on Day -8. Busulfan AUC 5,000 by vein on Days -6 to -3. Fludarabine 10 mg/m2 by vein on Days -6 to -3. Clofarabine 40 mg/m2 by vein on Days -6 to -3. Total body irradiation (TBI) delivered at 2Gy on Day -2. Stem cell infusion performed on Day 0. Cyclophosphamide 50 mg/kg by vein on Days +3 and +4. Tacrolimus 0.015 mg/kg/day by vein or mouth on Day +5. Mycophenolate mofetil 15 mg/kg/dose by vein or by mouth three times a day from Day +5 to Day+100.

    Interventions:
    • Drug: Busulfan
    • Drug: Fludarabine
    • Drug: Clofarabine
    • Radiation: Total Body Irradiation (TBI)
    • Biological: Stem Cell Infusion
    • Drug: Cyclophosphamide
    • Drug: Tacrolimus
    • Drug: Mycophenolate mofetil
    • Drug: Decitabine
    • Drug: Cytarabine
    • Drug: Idarubicin
  • Experimental: Matched Unrelated Donor Group

    Salvage Chemotherapy Before Transplant: Decitabine 20 mg/m2 by vein on Days 1 - 5. Cytarabine 1 g/m2 by vein on Days 6 - 10. Idarubicin 10 mg/m2 by vein on Days 6 - 8. Clofarabine 15 mg/m2 by vein on Days 6 - 9.

    Stem Cell Transplant: Test dose Busulfan 32 mg/m2 given by vein on Day -8. Busulfan AUC 5,000 by vein on Days -6 to -3. Fludarabine 10 mg/m2 by vein on Days -6 to -3. Clofarabine 40 mg/m2 by vein on Days -6 to -3. Thymoglobulin 2.0 mg/Kg by vein on Days -3 and -2. Stem cell infusion performed on Day 0.

    Interventions:
    • Drug: Busulfan
    • Drug: Fludarabine
    • Drug: Clofarabine
    • Drug: Thymoglobulin
    • Biological: Stem Cell Infusion
    • Drug: Decitabine
    • Drug: Cytarabine
    • Drug: Idarubicin
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Actual Enrollment  ICMJE
 (submitted: July 27, 2018)
11
Original Estimated Enrollment  ICMJE
 (submitted: May 7, 2015)
75
Estimated Study Completion Date  ICMJE September 2023
Estimated Primary Completion Date September 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Patients age 18-60 years.
  2. Patients with diagnosis of AML, judged primary refractory after up to 2 courses of AML induction therapy (> 5% blasts on day 21 (+/-7 days) bone marrow aspirate and/or biopsy from the beginning of induction chemotherapy, up to 42 days).
  3. Eastern Cooperative Oncology Group (ECOG) Performance Status </= 2.
  4. Adequate major organ function:, defined as: a) Serum creatinine </= 3 mg/dL; b) Total bilirubin </= 2.5 mg/dL; c) ALT (SGPT) </= 3 x ULN or </= 5 x ULN if related to disease; d) Cardiac ejection fraction >/= 40% (by either ECHO or MUGA).
  5. Willingness to have an allogeneic transplant.
  6. Patient or patient's legal representative able to provide written informed consent.
  7. Patients are required to meet the following criteria to proceed to AHSCT:
  8. Donor criteria: Availability of a donor either an HLA matched sibling donor (MSD) or a haploidentical (5-9/10 HLA matched); alternatively a 8/8 HLA matched unrelated donor (MUD) by high resolution typing is immediately available;
  9. Disease criteria: Day 21 (+/-7 days) bone marrow aspiration or biopsy from the beginning of salvage DCIA: a. In complete morphologic remission with <5% bone marrow blasts, or b. Aplastic (<10% bone marrow cellularity), and cytopenic with an absolute neutrophil count (ANC) less than 1,000/µL, or c. Low disease burden with < 30% BM blasts, with recovery of peripheral blood (PB) WBC (ANC>1,000/µL) and <5% circulating blasts.
  10. Adequate organ function criteria: a. Serum creatinine clearance >/= 50 ml/min (calculated by Cockcroft-Gault formula); b. Total bilirubin </= 2 times upper limit of normal (x ULN) (3 x ULN if considered to be due to leukemic involvement or Gilbert's syndrome); c. Alanine aminotransferase (ALT) </= 3 x ULN (5.0 x ULN if considered to be due to leukemic involvement); d. LVEF >/= 40% on ECHO or MUGA; e. DLCO >/= 50% predicted after correction for hemoglobin (must be performed in patients with history of smoking or lung disease;); DLCO may be omitted in patients without history of pulmonary disease if approved by the Study Chair.
  11. No active infection: Patients should be afebrile. If present, pulmonary infiltrates or other sites of infection must be improving on antibiotics. Patients should not require oxygen. Study Chair will be the arbiter of this criterion.

Exclusion Criteria:

  1. HIV positive; active hepatitis B or C.
  2. Uncontrolled active infections (viral, bacterial, and fungal); the Study Chair will be the final arbiter of this criterion.
  3. Patients with active secondary malignancy unless approved by the Study Chair.
  4. Liver cirrhosis.
  5. Active CNS involvement within the previous 2 months.
  6. Prior induction therapy with DAC + CIA.
  7. Positive pregnancy test in a woman with child bearing potential defined as not post-menopausal for 12 months or no previous surgical sterilization.
  8. Breast feeding women.
  9. Men must agree not to father a child and agree to use a condom if his partner is of child bearing potential.
  10. Inability to comply with medical therapy or follow-up.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 60 Years   (Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02441803
Other Study ID Numbers  ICMJE 2014-0358
NCI-2015-00849 ( Registry Identifier: NCI CTRP )
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party M.D. Anderson Cancer Center
Study Sponsor  ICMJE M.D. Anderson Cancer Center
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Stefan Ciurea, MD M.D. Anderson Cancer Center
PRS Account M.D. Anderson Cancer Center
Verification Date May 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP